Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525520 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
A Phase 2 study of Pruritus, sponsored by Escient Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT05525520: Completed Phase 2 study of Pruritus, sponsored by Escient Pharmaceuticals.
NCT05525520 is a Phase 2 study of Pruritus that has completed, run by Escient Pharmaceuticals. The registered enrollment target is 62 participants, below the 106-participant average among 12 other Pruritus trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05525520, a Phase 2 study of Pruritus, has completed, sponsored by Escient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)
Primary Outcome
Participants were asked to rate the severity of their worst level of itching in the past 24 hours using the daily WI-NRS, an 11-point scale ranging from 0 (no itching) to 10 (worst itching imaginable). Itching severity scores collected via the WI-NRS have been categorized in the as mild (\<4), moderate (≥4 to \<7), or severe (≥7). The average WI-NRS score using the daily values from the week before the first dose of study drug (including the WI-NRS score captured on Study Day 1 of dosing) served
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EP547
Study Locations (20)
California
- Southern California Research Center - Coronado
- Science 37 - Culver City
- California Liver Research Institute - Pasadena
Texas
- The Liver Institute at Methodist Dallas Medical Center - Dallas
- Liver Associates of Texas, PA - Houston
- Gastro Health & Nutrition - Katy
Louisiana
- Tulane University Health Sciences Center - New Orleans
- Ochsner Medical Center - New Orleans
New York
- NYU Grossman School of Medicine Gastroenterology and Hepatology - New York
- Montefiore Medical Center - The Bronx
Ohio
- Gastro Health Research - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Alabama
- University of Alabama Birmingham Hospital - Birmingham
Arizona
- Dignity Health Center for Clinical Research at St. Joseph Hospital - Phoenix
Florida
- University of Miami - Schiff Center for Liver Diseases - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2024-09-05 |
| Phase | Phase 2 |
What the finished NCT05525520 record still lists
NCT05525520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 106-participant average among 12 other Pruritus trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Pruritus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05525520 names 20 study sites across 13 states, led by California, Texas, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05525520 about?
NCT05525520 is a clinical study titled "Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis". This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)
What is the current status of trial NCT05525520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2022-10-06. Estimated completion is 2024-09-05.
What conditions does trial NCT05525520 study?
This clinical trial studies the following conditions: Pruritus.
What interventions are being tested in trial NCT05525520?
The interventions under investigation include: Placebo (DRUG), EP547 (DRUG).
Who is sponsoring clinical trial NCT05525520?
This trial is sponsored by Escient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05525520 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05525520's enrollment target sits among peer trials
62 4th of 12 higher than 8 of 12 other Pruritus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pruritus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
-
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
COMPLETED · Phase 2
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI